Major Cardiac Events in Patients and Relatives With Hereditary Hypertrophic Cardiomyopathy

[1]  P. Munroe,et al.  Prevalence of Hypertrophic Cardiomyopathy in the UK Biobank Population , 2021, JAMA cardiology.

[2]  Matthew W. Martinez,et al.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Journal of the American College of Cardiology.

[3]  J. Mogensen,et al.  Clinical and Genetic Investigations of 109 Index Patients With Dilated Cardiomyopathy and 445 of Their Relatives , 2020, Circulation. Heart failure.

[4]  P. Elliott,et al.  Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers , 2020, Journal of the American College of Cardiology.

[5]  B. Maron,et al.  Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. , 2019, Circulation.

[6]  R. Oldenburg,et al.  Outcomes of Contemporary Family Screening in Hypertrophic Cardiomyopathy , 2018, Circulation. Genomic and precision medicine.

[7]  Birgit Funke,et al.  Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel , 2018, Genetics in Medicine.

[8]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[9]  Martin Borggrefe,et al.  [2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy]. , 2014, Kardiologia polska.

[10]  Karen S. Frese,et al.  Atlas of the clinical genetics of human dilated cardiomyopathy. , 2014, European heart journal.

[11]  E. Behr,et al.  Burden of Sudden Cardiac Death in Persons Aged 1 to 49 Years: Nationwide Study in Denmark , 2014, Circulation. Arrhythmia and electrophysiology.

[12]  P. Elliott,et al.  Cardiac Myosin Binding Protein-C Mutations in Families With Hypertrophic Cardiomyopathy: Disease Expression in Relation to Age, Gender, and Long Term Outcome , 2012, Circulation. Cardiovascular genetics.

[13]  C. Semsarian,et al.  Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy. , 2011, International journal of cardiology.

[14]  R. Hauer,et al.  Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. , 2011, European heart journal.

[15]  Iacopo Olivotto,et al.  Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. , 2003, Journal of the American College of Cardiology.

[16]  C. Wippermann,et al.  Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe , 2000, Heart.

[17]  H Niimura,et al.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.

[18]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.